Journal article
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
European journal of cancer (1990), Vol.49(16), pp.3450-3461
11/2013
DOI: 10.1016/j.ejca.2013.06.033
PMID: 23886586
Abstract
Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions.
Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA25) (version 1). IVC cases were tested for p16INK4a by immunohistochemistry (CINtec histology kit, ROCHE).
An IVC was considered HPV driven if both HPV-DNA and p16INK4a overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95% confidence intervals (CI).
Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7% and 28.6% of the cases respectively. Amongst IVC cases, 25.1% were both HPV-DNA and p16INK4a positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) (N=1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC_WB) (N=326) were more likely to be HPV and p16INK4a positive (AP=69.5%, CI=63.6–74.8) versus KSCC (AP=11.5%, CI=9.7–13.5). HPV 16 was the commonest type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold).
Combined data from HPV-DNA and p16INK4a testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.
Details
- Title: Subtitle
- Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
- Creators
- Silvia de Sanjosé - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, SpainLaia Alemany - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, SpainJaume Ordi - Department of Pathology, CRESIB – Hospital Clínic, University of Barcelona, SpainSara Tous - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, SpainMaria Alejo - Hospital General d’Hospitalet, L’Hospitalet de Llobregat, SpainSusan M Bigby - Histopathology, Laboratory Services, Middlemore Hospital, Otahuhu, Auckland, New ZealandElmar Armin Joura - Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center, Vienna, AustriaPaula Maldonado - Instituto de Ginecologia da Universidad Federal do Rio de Janeiro, Rio de Janeiro, BrazilJan Laco - The Fingerland Department of Pathology, Charles University Faculty of Medicine and Faculty Hospital in Hradec Kralove, Czech RepublicIgnacio G Bravo - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, SpainAugust Vidal - Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, SpainNúria Guimerà - DDL Diagnostic Laboratory, Rijswijk, The NetherlandsPaul Cross - Department of Cellular Pathology, Queen Elizabeth Hospital, Gateshead, UKGerard V Wain - Gynaecological Oncology, Westmead Hospital, AustraliaKarl Ulrich Petry - Klinikum Wolfsburg, Wolfsburg, GermanyLuciano Mariani - Regina Elena Cancer Istitute, Rome, ItalyChristine Bergeron - Laboratoire Cerba, Department de Pathology, Cergy Pontoise, FranceVáclav Mandys - Department of Pathology, 3rd Faculty of Medicine and Faculty Hospital King’s Wineyards, Prague, Czech RepublicAdela Rosa Sica - Laboratorio de Anatomía patológica del hospital de la Mujer, Montevideo, UruguayAna Félix - Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa, PortugalAlp Usubutun - Medical School, Department of Pathology, Hacettepe University, Ankara, TurkeyMuhieddine Seoud - The American University of Beirut Medical Center, Beirut, LebanonGustavo Hernández-Suárez - Instituto Nacional de Cancerología, Bogotá, ColombiaAndrzej Marcin Nowakowski - Medical University of Lublin, Lublin, PolandGodfrey Wilson - Manchester Royal Infirmary, Manchester, UKVeronique Dalstein - CHU de Reims, Laboratoire Pol Bouin/INSERM UMR-S 903, Reims, FranceMonika Hampl - Department of Obstetrics and Gynecology, Heinrich Heine University of DuseseDuesseldorf, Duesseldorf, GermanyElena Sachiko Kasamatsu - Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, ParaguayLuis Estuardo Lombardi - Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva-CIESAR, Hospital General San Juan de Dios, Guatemala, GuatemalaLeopoldo Tinoco - Hospital Oncológico Solca, Quito-, EcuadorIsabel Alvarado-Cabrero - Instituto Mexicano del Seguro Social, DF, MexicoMyriam Perrotta - Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaNeerja Bhatla - All India Institute of Medical Sciences, New Delhi-110029, IndiaTheodoros Agorastos - Aristotle University of Thessaloniki, Thessaloniki, GreeceCharles F Lynch - Department of Epidemiology, College of Public Health, University of Iowa, IA, USAMarc T Goodman - Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, USAHai-Rim Shin - National Cancer Center, Seoul, South KoreaHalina Viarheichyk - Gomel State Medical University, Gomel, BelarusRobert Jach - Jagiellonian University Medical College, Krakow, PolandM.O.L. Eugenia Cruz - Centro Regional de Oncologia Coimbra, Coimbra, PortugalJulio Velasco - Hospital San Agustín, Avilés, SpainCarla Molina - Centro de Oncología Preventiva, Facultad de Medicina, Universidad de Chile, Santiago de Chile, ChileJacob Bornstein - Western Galilee Hospital and Faculty of Medicine of Bar-Ilan University, Nahariya, Israel, IsraelAnnabelle Ferrera - Escuela de Microbiología, Universidad Nacional Autónoma de Honduras, Tegucigalpa, HondurasEfren Javier Domingo - University of the Philippine College of Medicine General Hospital, Manila, PhilippinesCheng-Yang Chou - National Cheng Kung University Medical College, Taiwan Association of Gynecologic Oncologists, Tainan, TaiwanAdekunbiola F Banjo - Lagos University Teaching Hospital, Idi-Araba, Lagos, NigeriaXavier Castellsagué - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, SpainMichael Pawlita - Virus-Host Interactions of Polyoma and Papilloma Viruses, DKFZ, Heidelberg, GermanyBelén Lloveras - Hospital del Mar, Barcelona, SpainWim G.V Quint - DDL Diagnostic Laboratory, Rijswijk, The NetherlandsNubia Muñoz - Emeritus Hospital Universitario del Valle, Cali, ColombiaF. Xavier Bosch - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, SpainHPV VVAP study group
- Resource Type
- Journal article
- Publication Details
- European journal of cancer (1990), Vol.49(16), pp.3450-3461
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/j.ejca.2013.06.033
- PMID
- 23886586
- ISSN
- 0959-8049
- eISSN
- 1879-0852
- Language
- English
- Date published
- 11/2013
- Academic Unit
- Epidemiology
- Record Identifier
- 9983995036002771
Metrics
16 Record Views